Axsome Therapeutics (AXSM) Cost of Revenue (2022 - 2026)

Axsome Therapeutics has reported Cost of Revenue for 5 years, with the latest figure at $14.7 million in Q1 2026.

• Quarterly Cost of Revenue rose 50.42% year-over-year to $14.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.4 million (up 42.45% YoY) and the FY2025 annual result came in at $47.5 million, up 42.56% from the prior year.
• Cost of Revenue grew to $14.7 million in Q1 2026 per AXSM's latest filing, from $12.3 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $14.7 million in Q1 2026 and troughed at $983000.0 in Q2 2022.
• A 5-year average of $7.9 million and a median of $7.8 million in 2023 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2023 and 2024: Cost of Revenue surged 367.85% in 2023, then retreated 16.66% in 2024.
• Over 5 years, Cost of Revenue stood at $2.3 million in 2022, then jumped by 222.04% to $7.4 million in 2023, then soared by 42.5% to $10.5 million in 2024, then advanced by 17.26% to $12.3 million in 2025, then grew by 19.43% to $14.7 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $14.7 million, $12.3 million, and $11.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.